Navigation Links
Orexigen® Therapeutics Reports Fourth Quarter and Year Ended December 31, 2010 Financial Results
Date:3/10/2011

ponse Letter from the FDA for its New Drug Application.  The company is in the process of determining the next steps for Contrave.  The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.

Forward-Looking Statements  

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the potential for, and timing of, approval for Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's ability to conduct a preapproval cardiovascular outcomes trial, Orexigen's ability to demonstrate that the risk of major adverse cardiovascular events in overweight and obese subjects treated with Contrave does not adversely affect the product candidate's benefit-risk profile; the potential for early termination of the collaboration agreement between Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of an ND
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
2. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
3. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
4. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
5. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
6. Orexigen® Therapeutics to Speak at Rodman & Renshaw Annual Global Investment Conference
7. Orexigen® Therapeutics to Speak at Fifth Annual JMP Securities Healthcare Conference
8. Orexigen® Therapeutics Reports Third Quarter 2010 Financial Results
9. Orexigen® Therapeutics Investigational Drug Contrave® Receives Positive Recommendation from FDA Advisory Committee for Treatment of Obesity
10. Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer
11. Orexigen® Therapeutics Schedules March 10, 2011 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 /CNW/ - On Aug. ... , the Canadian Medical Association (CMA) voted on ... any plant material, including medicinal cannabis. Bedrocan Cannabis Corp., ... supportive of the CMA motion. The CMA ... particular hazards associated with smoking any plant material, including ...
(Date:8/22/2014)... Aug. 22, 2014 Research and Markets ... Research Products: Opportunities, Tools & Technologies" report to ... stem cell research products or you wish to expand ... lucrative this market is. The authors know you want ... effectively to scientists, to generate improved revenues and take ...
(Date:8/22/2014)... Mich. , Aug. 22, 2014  Dr. ... Who with the Diamond Lifetime Achievement Award in the ... as CEO of Cardiovascular Clinical Associates. Dr. ... in managing all major aspects of the business; overseeing ... well as primary coronary intervention. In addition, he is ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
... CARLSBAD, Calif., Oct. 18 Excaliard Pharmaceuticals, Inc. ... as Chairman of its Board of Directors. Mr. ... years of experience in successfully developing and commercializing ... field.  Excaliard Pharmaceuticals, Inc. is a biotechnology company ...
... Bend Research Inc. ( www.bendres.com ), a ... announced today it has extended its drug discovery ... Company ( www.bms.com ) (NYSE: BMY ... Under the terms of the 3-year agreement, Bristol-Myers ...
Cached Medicine Technology:Excaliard Pharmaceuticals Appoints Thomas Wiggans to Chairman of the Board 2Bend Research Announces Extension of Drug-Discovery Enablement and Development Services Agreement With Bristol-Myers Squibb 2
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... that uses university-proven research to show people how they can ... lean muscle in only a matter of weeks has caught ... , “Ben Pakulski is one of the most well-known bodybuilders ... get the body he has today, that in itself is ...
(Date:8/22/2014)... a complex autoimmune disease that affects 1 to ... only cope with pain, disability and joint disfigurements, ... family life and marital functioning. While many pharmacological ... disability is common. In addition, some patients avoid ... side effects. Because of this, there is interest ...
(Date:8/22/2014)... 2014 Testosterone treatment lawsuits ( ... courts on behalf of men who allegedly suffered ... prescription low testosterone therapies, Bernstein Liebhard LLP reports. ... filed against Pfizer Inc. on July 31st by ... issues due to his use of Depo-Testosterone. (Case ...
(Date:8/22/2014)... UK (PRWEB) August 22, 2014 The ... recent past, specifically in the developing world, has led ... and the number of deaths due to AIDS globally. ... declining, the number of new patients becoming affected by ... conscious efforts being undertaken by all related organisations and ...
(Date:8/22/2014)... Ohio (PRWEB) August 22, 2014 Dayton Children's ... care tower as part of a $141 million campus renewal. ... patient care tower were unveiled to the public. , ... facilities plan that will create a campus that meets the ... future. These new care spaces will embody Dayton Children’s unique ...
Breaking Medicine News(10 mins):Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 2Health News:Worldwide HIV Infection Drug Market Examined in New Kuick Research Report Published at MarketPublishers.com 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5
... cells, stem cells derived from human placenta left over ... when they interacted with one kind of melatonin receptor, ... cells were transplanted into laboratory test tube and animal ... perform similarly when interacting with melatonin receptor MT2. ...
... 1, 2011) Positron emission tomography (PET) can ... kinase inhibitor vandetanib, helping to define the therapy ... according to research published in the February issue ... Currently being tested in clinical trials, vandetanib inhibits ...
... Society for Therapeutic Radiology and Oncology (ESTRO), the European ... for Medical Oncology (ESMO) in collaboration with other European ... on the 3rd International Conference on innovative approaches In ... on multidisciplinarity and innovation, this meeting will specifically cover ...
... and ultrasound can mean more targeted breast biopsies for ... and possibly saving those patients from undergoing a second ... Patients with early breast cancer undergo a sentinel lymph ... said Dr. Ali Sever, lead author of the study. ...
... -- Among injection drug users, new cases of HIV infection ... number of new infections from the hepatitis C virus have ... The findings suggest that efforts -- such as needle exchange ... of infectious diseases have been successful against HIV but more ...
... professionals have talked about youth pitching injuries and the stress ... new, 10-year study published in the February issue of the ... participants who pitched more than 100 innings in a year ... study proved a direct link between innings pitched in youth ...
Cached Medicine News:Health News:Transplanted human placenta-derived stem cells show therapeutic potential in stroke models 2Health News:PET scans may allow early prediction of response to targeted therapy of thyroid cancer 2Health News:3rd international conference on innovative approaches in head and neck oncology 2Health News:Microbubble ultrasound and breast biopsies 2Health News:Infectious Disease Experts Call for More Focus on Hepatitis C 2Health News:New 10-year study confirms too many pitches strike out youth athletes early 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: